Bml (4694) · InitiativeSoftened
Expansion into China's clinical laboratory testing business
First written in FY2016. 2 of 3 entries say "Softened", first in FY2017. Latest entry: FY2020.
3entries
5years
0from disclosures
How it moved
Same theme, other companies
Joint venture entry into and withdrawal from China's contract clinical testing marketA theme 2 companies write about · 2 as a headwind · 0 as a tailwind
Bml moved to the "Worse" side of this theme in 2017.
0 other companies' latest entry also says "Softened".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
- FY2020SoftenedAnnual report
「Investment in 上海千麦博米楽医学検験所有限公司 (China), with the ownership interest declining from 40% at the time to 10% currently.」
The ownership interest in the Chinese clinical laboratory testing company declined further from the previously reported 25% to 10% currently. In addition, because the ownership interest declined during the consolidated fiscal year, the company was removed from the list of equity-method affiliates. - FY2017SoftenedAnnual report
「December 2013: Opened a representative office in Shanghai, China. May 2014: Acquired a stake in 上海千麦博米楽医学検験所有限公司 (China), holding 40% at the time and 25% currently.」
Reports that the ownership interest in the Chinese clinical laboratory testing company declined from 40% at the time to 25% currently. - FY2016First statedAnnual report
「December 2013: Opened a representative office in Shanghai, China. May 2014: Acquired a 40% stake in 上海千麦博米楽医学検験所有限公司 (China).」
Reports the overseas expansion through the opening of a Shanghai office and a 40% investment in a Chinese clinical laboratory testing company.